WO2013113915A1 - Process for preparing n-(4-cyclohexyl-3-trifluoromethyl-benzyloxy)-acetimidic acid ethyl ester - Google Patents

Process for preparing n-(4-cyclohexyl-3-trifluoromethyl-benzyloxy)-acetimidic acid ethyl ester Download PDF

Info

Publication number
WO2013113915A1
WO2013113915A1 PCT/EP2013/052106 EP2013052106W WO2013113915A1 WO 2013113915 A1 WO2013113915 A1 WO 2013113915A1 EP 2013052106 W EP2013052106 W EP 2013052106W WO 2013113915 A1 WO2013113915 A1 WO 2013113915A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
process according
reacting
bromo
Prior art date
Application number
PCT/EP2013/052106
Other languages
French (fr)
Inventor
Fabrice Gallou
Joerg Matthias SEDELMEIER
Caspar Vogel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MX2014009352A priority Critical patent/MX350211B/en
Priority to JP2014555236A priority patent/JP6209541B2/en
Priority to KR1020147024290A priority patent/KR20140121469A/en
Priority to CA2862375A priority patent/CA2862375A1/en
Priority to CN201380007968.0A priority patent/CN104105687B/en
Priority to EP13702472.5A priority patent/EP2809645A1/en
Priority to US14/376,143 priority patent/US9604914B2/en
Priority to AU2013214103A priority patent/AU2013214103B2/en
Application filed by Novartis Ag filed Critical Novartis Ag
Priority to RU2014135795A priority patent/RU2014135795A/en
Priority to BR112014018756A priority patent/BR112014018756A8/en
Publication of WO2013113915A1 publication Critical patent/WO2013113915A1/en
Priority to IL233791A priority patent/IL233791A0/en
Priority to IL249227A priority patent/IL249227A0/en
Priority to US15/432,213 priority patent/US20170166517A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32Oximes
    • C07C251/50Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals
    • C07C251/52Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals of hydrocarbon radicals substituted by halogen atoms or by nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C17/00Preparation of halogenated hydrocarbons
    • C07C17/013Preparation of halogenated hydrocarbons by addition of halogens
    • C07C17/04Preparation of halogenated hydrocarbons by addition of halogens to unsaturated halogenated hydrocarbons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C17/00Preparation of halogenated hydrocarbons
    • C07C17/093Preparation of halogenated hydrocarbons by replacement by halogens
    • C07C17/10Preparation of halogenated hydrocarbons by replacement by halogens of hydrogen atoms
    • C07C17/12Preparation of halogenated hydrocarbons by replacement by halogens of hydrogen atoms in the ring of aromatic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C17/00Preparation of halogenated hydrocarbons
    • C07C17/093Preparation of halogenated hydrocarbons by replacement by halogens
    • C07C17/10Preparation of halogenated hydrocarbons by replacement by halogens of hydrogen atoms
    • C07C17/14Preparation of halogenated hydrocarbons by replacement by halogens of hydrogen atoms in the side-chain of aromatic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C17/00Preparation of halogenated hydrocarbons
    • C07C17/26Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C17/00Preparation of halogenated hydrocarbons
    • C07C17/35Preparation of halogenated hydrocarbons by reactions not affecting the number of carbon or of halogen atoms in the reaction
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C17/00Preparation of halogenated hydrocarbons
    • C07C17/35Preparation of halogenated hydrocarbons by reactions not affecting the number of carbon or of halogen atoms in the reaction
    • C07C17/354Preparation of halogenated hydrocarbons by reactions not affecting the number of carbon or of halogen atoms in the reaction by hydrogenation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C22/00Cyclic compounds containing halogen atoms bound to an acyclic carbon atom
    • C07C22/02Cyclic compounds containing halogen atoms bound to an acyclic carbon atom having unsaturation in the rings
    • C07C22/04Cyclic compounds containing halogen atoms bound to an acyclic carbon atom having unsaturation in the rings containing six-membered aromatic rings
    • C07C22/08Cyclic compounds containing halogen atoms bound to an acyclic carbon atom having unsaturation in the rings containing six-membered aromatic rings containing fluorine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C249/00Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C249/04Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C249/00Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C249/04Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes
    • C07C249/12Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes by reactions not involving the formation of oxyimino groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C25/00Compounds containing at least one halogen atom bound to a six-membered aromatic ring
    • C07C25/18Polycyclic aromatic halogenated hydrocarbons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C29/00Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
    • C07C29/132Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group
    • C07C29/136Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH
    • C07C29/14Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH of a —CHO group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C29/00Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
    • C07C29/132Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group
    • C07C29/136Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH
    • C07C29/147Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH of carboxylic acids or derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C29/00Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
    • C07C29/44Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring increasing the number of carbon atoms by addition reactions, i.e. reactions involving at least one carbon-to-carbon double or triple bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/40Halogenated unsaturated alcohols
    • C07C33/50Halogenated unsaturated alcohols containing six-membered aromatic rings and other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/27Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00Compounds having —CHO groups
    • C07C47/52Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/546Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings polycyclic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00Compounds having —CHO groups
    • C07C47/52Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/55Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/82Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/15Preparation of carboxylic acids or their salts, halides or anhydrides by reaction of organic compounds with carbon dioxide, e.g. Kolbe-Schmitt synthesis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Definitions

  • This invention relates to novel processes for synthesizing N-(4-cyclohexyl-3- trifluoromethyl-benzyloxy)-acetimidic acid ethyl ester and to intermediates that are used in such processes.
  • the compound N-(4-cyclohexyl-3-trifluoromethyl-benzyloxy)-acetimidic acid ethyl ester is an intermediate in the synthesis of the pharmaceutically active compound 1 - ⁇ 4-[1-(4-cyclohexyl- 3-trifluoromethyl-benzyloxyimino)-ethyl-benxyl ⁇ -azetidine-3-carboxylic acid (“Compound A”).
  • Compound A is a sphingosine-1 -phosphate (“S1 P") modulator that is useful for the treatment of immunological disorders, e.g., multiple sclerosis.
  • S1 P sphingosine-1 -phosphate
  • Compound A, methods of synthesizing Compound A and methods of treating various disorders using Compound A are referred to in United States Patent 7,939,519, which issued on May 10, 201 1 . This patent is incorporated herein by reference in its entirety.
  • This invention also relates to the compound having the formula
  • This compound is useful as an intermediate in the syntheses of both the compound of formula I and Compound A.
  • This invention also relates to compounds of the formula
  • X 1 is bromo, chloro, iodo or fluoro, preferably bromo.
  • This invention also relates to the compound of formula
  • This compound is useful as an intermediate in the syntheses of both Compound A and the compound of formula I.
  • This invention also relates to the compound of formula
  • This compound is useful as an intermediate in the syntheses of both the compound of formula I and Compound A.
  • This invention also relates to the compound of formula
  • This compound is useful as an intermediate in the syntheses of both Compound A and the compound of formula I.
  • This invention also relates to the compound of formula
  • This compound is useful as an intermediate in the syntheses of both Compound A and the compound of formula I.
  • This invention also relates to the compound of formula
  • This compound is useful as an intermediate in the synthesis of Compound A from the compound of formula I.
  • This invention also relates to a process for preparing the compound of formula I, as described above, comprising reacting a compound having the formula
  • X 2 is bromo, chloro, iodo, mesylate, tosylate, brosylate, triflate or another suitable leaving group, preferably bromo, with the compound of formula
  • Et is ethyl, in the presence of: (i) a strong base, preferably sodium hydride or potassium t-butoxide or, alternatively, a weaker base such as potassium carbonate or sodium carbonate; and (ii) a catalytic amount of 4-dimethylamino pyridine.
  • a strong base preferably sodium hydride or potassium t-butoxide or, alternatively, a weaker base such as potassium carbonate or sodium carbonate
  • a catalytic amount of 4-dimethylamino pyridine preferably 4-dimethylamino pyridine.
  • This invention also relates to the above method for preparing the compound of formula I from a compound of the formula IX, wherein the starting material of formula IX is prepared by a process comprising:
  • X is bromo or iodo, preferably bromo, with an appropriate Grignard reagent (preferably, when X is bromo, i-propylmagnesiumchloride lithium chloride complex) and cyclohexanone to form the compound of formula
  • X 1 is bromo, chloro, iodo or fluoro, preferably bromo, by reacting the compound of formula V with 1 ,3-dibromyl-5,5-diethylhydantoin when X 1 is bromo, or with the appropriate analogous compound when X 1 is chloro, fluoro or iodo, in the presence of an acid, preferably trifluoroacetic acid or a mixture of sulfuric acid and trifluoroacetic acid;
  • This invention also relates to the above method for preparing a compound of the formula I from a compound of the formula IX, as described above, wherein the starting material of formula IX is prepared by a process comprising:
  • a palladium catalyst preferably palladium acetate, a phosphine, preferably triphenylphosphine, and a base, preferably, sodium methylate, to form the compound of formula
  • This invention also relates to a process for preparing the compound of formula I, as described above, from a compound of formula IX, wherein the starting material of formula IX is prepared by a process comprising:
  • X 5 is chloro, bromo or iodo
  • This invention also relates to the process for forming the compound of formula I from a compound of the formula IX, as described above, wherein the starting material of formula IX is prepared by a process comprising:
  • X, X 1 , X 2 , X 3 , X 4 and X 5 are defined as they are defined above.
  • Scheme 1 illustrates a method of synthesizing the compound of formula I from a compound of the formula IX, wherein the compound of formula IX is prepared by a seven step process starting with a compound of formula II.
  • This method is advantageous in that it allows for the large scale production of the fragment of Compound A that is provided by the compound of formula I.
  • a compound of the formula II, wherein X is bromo, chloro or iodo, preferably bromo is reacted with an appropriate Grignard reagent, preferably an i- propylmagnesium chloride - lithium chloride complex, and cyclohexanone to form the compound of formula III.
  • the Grignard compound is preferably formed by reaction with metallic magnesium, while, when X is iodo, the Grignard compound is preferably formed by an exchange with i-propylmagnesium chloride).
  • This reaction is carried out in a solvent such as diethyl ether, tetrahydrofuran (THF), or an alkane such as hexane or heptane, or a mixture of two or more of the foregoing solvents, preferably a mixture of heptane and THF, at a temperature from about -20°C to about 30°C, preferably from about 5°C to about 10°C.
  • the compound of formula III is then reacted, preferably in situ, with a strong acid such as sulfuric acid or phosphoric acid, preferably sulfuric acid, at an internal temperature (IT) from about 10°C to about 50°C, preferably from about 20°C to about 25°C, to form the compound of formula IV, which is then subjected to catalytic hydrogenation, using methods well known to those of skill in the art (e.g., palladium on carbon catalyst in a methanol solvent at a temperature from about 20°C to about 50°C and a pressure of about 2 - 20 bar, to produce the compound of formula V.
  • the catalytic hydrogenation is also preferably conducted in situ.
  • Bromination of the compound of formula V preferably in situ, at a temperature from about -10°C to about 20°C, preferably from about 0°C to about 5°C, yields the compound of formula VI wherein X 1 is bromo.
  • This bromination can be accomplished by reacting the compound of formula V with 1 ,3-dibromo-5,5-dimethylhydantoin or N-bromosuccinimide in an acid such as sulfuric acid, trifluoroacetic acid or a mixture of sulfuric and trifluoroacetic acids, at a temperature from about -10°C to about 5°C, preferably from about 0°C to about 5°C.
  • the resulting halogenated compound of formula VI can then be converted into the corresponding carboxylic acid of formula VII by reacting it, preferably in situ, with an appropriate Grignard reagent (preferably a butyl lithium butyl magnesium chloride complex or a butyl lithium i- propylmagnesiumchloride complex) and carbon dioxide. Conducting this halogenation reaction with the appropriate analogous reagents will yield the corresponding compounds of formula VI wherein X is chloro, fluoro or iodo.
  • the carbon dioxide is preferably bubbled through the reaction mixture. Suitable temperatures for this reaction range from about -20°C to about 20°C, preferably from about -5°C to about 5°C.
  • Suitable solvents include diethyl ether, THF, methyltetrahydrofuran and alkanes such as heptane or hexane, with THF being preferred.
  • THF methyltetrahydrofuran
  • alkanes such as heptane or hexane, with THF being preferred.
  • the aldehyde (VIIA) corresponding to the carboxylic acid of formula VII is formed.
  • This aldehyde is a liquid at room temperature, making purification of the aldehyde by crystallization impossible. Therefore, when the aldehyde is formed and carried forward in the process, as described below, impurities from the preceding steps, including the unwanted regioisomers of compound IV, will be carried through to the formation of the compound of formula I.
  • Reduction of the compound of formula VII, VIIA or VIII yields the compound of formula VIII.
  • This reduction can be accomplished using a number of reducing agents well known to those of skill in the art (e.g., borane tetrahdrofurane complex, sodium borohydride/aluminum trichloride, aluminum hydride, lithium trimethoxyborohydride or lithium aluminum hydride).
  • reducing agents well known to those of skill in the art
  • Lithium aluminum hydride is preferred. This reaction is generally carried out at a temperature from about -10°C to about 60°C, preferably from about 20°C to about 50°C.
  • Suitable solvents include ethers (e.g., diethyl ether, dipropyl ether or THF), toluene or alkanes (e.g., heptane, hexane or cyclohexane), or a mixture one or more of the foregoing solvents.
  • ethers e.g., diethyl ether, dipropyl ether or THF
  • toluene or alkanes e.g., heptane, hexane or cyclohexane
  • a miixture of toluene and THF is preferred.
  • the compound of formula VIII can be converted into the desired compound of formula IX wherein the hydroxide group is replaced with a leaving group such as bromine, chlorine, mesylate, tosylate, trilate, brosylate, phosphonate or another suitable leaving group.
  • a leaving group such as bromine, chlorine, mesylate, tosylate, trilate, brosylate, phosphonate or another suitable leaving group.
  • Leaving groups and methods of adding them to organic compounds are well known to those of skill in the art. (See Wuts, Peter G. M. and Greene, Theodore W., Greene's Protective Groups in Organic Synthesis, 4 th Edition, Wiley, 2006, Print ISBN: 978-0-471-69754-1 , Online ISBN: 9780470053485).
  • Bromine is a preferred leaving group.
  • Bromine, chlorine and iodine can be added by reacting the compound of formula VIII with hydrogen bromide, hydrogen chloride, or hydrogen iodide, respectively.
  • This reaction is generally carried out in a solvent such as acetic acid, acetic anhydride, or sulfuric acid, preferably a mixture of acetic acid and acetic anhydride, at a temperature from about 0°C to about 60°C, preferably from about 20°C to about 30°C.
  • Mesylate, triflate, tosylate and brosylate groups can be added by reacting the compound of formula VIII with, respectively, mesyl chloride, trifluoromesyl chloride, tosyl chloride and brosyl chloride in a solvent, e.g., an ether such as diethyl ether, dipropyl ether or THF, toluene or an alkane such as heptane, hexane or cyclohexane, or a mixture of one or more of the foregoing solvents, with a mixture of toluene and THF being preferred, at a temperature from about -10°C to about 60°C, preferably from about 0°C to about 20°C, in the presence of a base such as triethylamine, ⁇ , ⁇ -diisopropylethylamine, or pyridine.
  • a solvent e.g., an ether such as diethyl ether, dipropy
  • this reaction can be conducted in a two phase system using an aqueous base such as sodium hydroxide, sodium carbonate, potassium hydroxide or potassium carbonate, and an organic solvent such as toluene, methylene chloride or alkanes such as heptane, hexane or cyclohexane, or a mixture thereof, with toluene being preferred.
  • an aqueous base such as sodium hydroxide, sodium carbonate, potassium hydroxide or potassium carbonate
  • an organic solvent such as toluene, methylene chloride or alkanes such as heptane, hexane or cyclohexane, or a mixture thereof, with toluene being preferred.
  • the resulting compound of formula IX can be converted into the compound of formula I by reacting it with the compound of formula X
  • Et is ethyl, in the presence of a strong base such as sodium hydride or potassium t- butoxide, lithium diisopropylamide, or potassium, lithium or sodium hexamethyldisilazide, preferably, sodium hydride or potassium t-butoxide, in a reaction inert solvent such as dimthylformamide (DMF), N-methylpyrrolidone (NMP), THF, methyltetrahydrofurane, toluene, an alkane such as hexane or heptane, a dialkyl ether such as ethyl ether, diiosopropylether, t- butylmethyl ether or methylcyclopentylether, or a mixture of two or more of the foregoing solvents, preferably, THF, at a temperature from about -29°C to about 40°C, preferably from about 0°C to about 10°C.
  • a strong base such as sodium hydr
  • the above reaction can be carried in the presence of a weaker base such as potassium carbonate, sodium carbonate, and a catalytic amount of 4- dimethylaminopyridine (DMAP), at the temperatures indicated immediately above, in a solvent such as acetone, methylethylketone, or cyclohexanone, preferably acetone.
  • a weaker base such as potassium carbonate, sodium carbonate, and a catalytic amount of 4- dimethylaminopyridine (DMAP)
  • DMAP 4- dimethylaminopyridine
  • Scheme 2 provides an alternate method of synthesizing the compound of formula IX. This process, which involves only three steps, is also useful for large scale production.
  • the compound of formula XI, wherein X 4 is bromo, chloro or iodo, and the boronic acid of formula XII are subjected to a Suzuki Coupling reaction.
  • This reaction is generally conducted in the presence of a palladium catalyst such as tetrakis(triphenylphoshine)palladium(0) or a mixture of a palladium (II) salt (e.g., palladium dichloride, palladium diacetate, or bistriphenylphosphinepalladium dichloride) and a phosphine (e.g., triphenylphosphine, tri-t-butylphosphine or tricyclohexylphosphine), and a base such as sodium methylate, potassium carbonate, cesium carbonate, or potassium t-butoxide, preferably sodium methylate, at a temperature from about 10°C to about 140°C, preferably from about 90°C to about 1 10°C.
  • a palladium catalyst such as tetrakis(triphenylphoshine)palladium(0) or a mixture of a palladium (II) salt (e.g., palla
  • Suitable solvents for this reaction include dimethylformamide (DMF), dioxane, alcohols such as ethanol, methanol or i-propanol, toluene and esters such as ethylacetate and i-propylacetate. Methanol is preferred.
  • DMF dimethylformamide
  • dioxane alcohols such as ethanol, methanol or i-propanol
  • toluene and esters such as ethylacetate and i-propylacetate.
  • Methanol is preferred.
  • the resulting compound of formula XIII is then subjected to catalytic hydrogenation, using methods well known to those of skill in the art (e.g., palladium on carbon catalyst in an acetic acid solvent at about 25°C and a pressure of about 1 - 20 atm) to produce the compound of formula XIV.
  • Conversion of the compound of formula XIV to the desired compound of formula IX is accomplished by subjecting the compound of formula XIV to a halogenation reaction.
  • the halogenation can be via a radical bromination or radical chlorination reaction, to produce a compound of the formula IX wherein X 2 is, respectively, chloro or bromo.
  • the reaction is a radical bromination, which is carried out by reacting the compound of formula XIV with N-bromosuccinimide, bromine, or 1 ,3-dimthyl-2,5-dibromohydantoine and a radical starter such as azoisobutyronitrile, preferably, N-bromosuccinimide, in a halogenated solvent such as dichloromethane or chlorobenzene, acetonitrile, i-ppropylacetate, or an alkane such as hexane, heptane or cyclohexane, preferably acetonitrile.
  • a radical bromination which is carried out by reacting the compound of formula XIV with N-bromosuccinimide, bromine, or 1 ,3-dimthyl-2,5-dibromohydantoine and a radical starter such as azoisobutyronitrile, preferably, N-bromosuccinimide, in
  • the reaction temperature can range from about -20°C to about 50°C, and is preferably about 20°C. Radical chlorination can be carried out under similar conditions, using suitable chlorinated reactants such as N-chlorosuccinimide or chlorine, preferably N-chlorosuccinimide.
  • Scheme 3 provides another alternate method of synthesizing compounds of the formula IX. This process, which involves only four steps, is also useful for large scale production.
  • a compound of the formula XV wherein X 5 is chloro, bromo or iodo
  • a strong reducing agent e.g., borane tetrahdrofurane complex, sodium borohydride/aluminum trichloride, aluminum hydride, lithium trimethoxyborohydride or lithium aluminum hydride
  • a strong reducing agent e.g., borane tetrahdrofurane complex, sodium borohydride/aluminum trichloride, aluminum hydride, lithium trimethoxyborohydride or lithium aluminum hydride
  • X 5 is, respectively, chloro, bromo or iodo.
  • This reaction is generally carried out at a temperature from about -10°C to about 60°C, preferably from about 20°C to about 50°C.
  • Suitable solvents include ethers such as diethyl ether, dipropyl ether or THF, toluene and alkanes such as heptane, hexane or cyclohexane, or a mixture thereof, with a mixture of toluene and THF being preferred.
  • the compound of formula XVII can be converted into the compound of formula VIII via catalytic hydrogenation, using conditions well known to those of skill in the art (e.g., palladium on carbon catalyst in an acetic acid solvent at about 25°C and a pressure of about 1 - 20 atm).
  • the conversion of the compound of formula VIII to the desired compound of formula IX can be accomplished as described above in the discussion of reaction Scheme I.
  • Scheme 4 illustrates another alternate method of synthesizing the compound of formula IX. This process also involves only four steps and is also useful for large scale production.
  • a compound of the formula XV, wherein X 5 is chloro, bromo or iodo, and the boronic acid of formula XII are subjected to a Suzuki Coupling reaction, using conditions well known to those of skill in the art and referred to above in the discussion of Scheme 2, to form the compound of formula XIX.
  • the compound of formula XIX is then subjected to catalytic hydrogenation, using conditions well known to those of skill in the art (e.g., palladium on carbon catalyst in an acetic acid solvent at about 25°C and a pressure of about 1 -20 atm), to produce the compound of formula VII, which can then be converted into the desired compound of formula IX via the compound of formula VIII, as described above in the discussion of the reaction chain VII ⁇ VIII ⁇ IX in Scheme 1 .
  • catalytic hydrogenation using conditions well known to those of skill in the art (e.g., palladium on carbon catalyst in an acetic acid solvent at about 25°C and a pressure of about 1 -20 atm), to produce the compound of formula VII, which can then be converted into the desired compound of formula IX via the compound of formula VIII, as described above in the discussion of the reaction chain VII ⁇ VIII ⁇ IX in Scheme 1 .
  • a process by which Compound A can by synthesized from the compound of formula I is depicted in Scheme 5.
  • a solution of the compound of formula I in a solvent such as methanol, propanol or i-propanol and at a temperature from about -20°C to about 40°C, preferably at about 20°C is treated with hydrochloric acid or sulfuric acid, preferably hydrochloric acid, to generate the oxime of formula XX, which is then reacted with compound of formula XXI to form the compound of formula XXII.
  • the reaction of the compounds of formulas XX and XXI is generally conducted in an alcoholic solvent such as methanol, ethanol, isopropanol, or butanol.
  • Suitable reaction temperatures can range from about 0°C to about 60°C, with the preferred temperature being from about 20°C to about 40°C.
  • a solvent such as toluene, acetonitrile, methylene chloride, or alkanes such as hexane, heptanes or cyclohexane, or mixture of two or more of the foregoing solvents, preferably a mixture of toluene and ethyl acetate, and oxidized to form the compound of formula XXIII by the addition of an aqueous solution of potassium bromide and potassium bicarbonate and a catalytic amount of TEMPO (2,2,6,6-tetramethylpiperidine 1-oxyl) or poly[[6-[(1 , 1 ,3,3-tetramnethylbutyl)amino]- 1 ,3,5-triazine-2,4-diyl
  • TEMPO 2,2,6,6-tetramethylpiperidine 1-
  • This reaction is generally conducted at a temperature from about -20°C to about 50°C, with the preferred temperature being from about 10°C to about 20°C.
  • the compound of formula XXII in a solution of heptanes can be oxidized to form the compound of formula XXIII by the addition of manganese dioxide.
  • Reductive amination of the compound of formula XXIII using methods well known to those of skill in the art, preferably with azetidine-3-carboxylic acid and sodium triacetoxyborohydride in methanol, followed by salt formation using methods well known to those of skill in the art, e.g., with fumaric acid in ethanol, followed by recrystallization from acetone/water, yeilds the hemifumarate salt of Compound A.
  • the phases were separated, the aqueous phase extracted with 14.2ml heptanes and the combined organic phases were washed with 13.5ml water.
  • the organic phase was concentrated to a volume of 120ml and 42.1 g H 2 S0 4 90% were added within 1 h keeping IT at 20 - 25°C.
  • the resulting mixture is stirred at high speed until the conversion from compound III to compound IV is complete. Then the phases were separated, the sulfuric acid phase extracted with 10ml heptanes.
  • reaction was quenched by the drop wise addition of 160ml 2M H 2 S0 4 , keeping IT at -5- 20°C.
  • the phases were separated and the organic phase was washed with 2 times 100ml water and concentrated to a volume of approx. (approximately) 160ml.
  • a solvent change to toluene was performed.
  • the volume of the toluene solution was then adjusted to about 180ml and heated until a clear solution was obtained.
  • 4-cyclohexyl-3- trifluoromethyl-benzoic acid crystallized out and was isolated by filtration followed by drying in a vacuum oven at 60°C over night.
  • Example 6 Synthesis of 4-Bromomethyl-1-cvclohexyl-2-trifluoro-methyl-benzene
  • IT 20 - 25°C.
  • the mixture was then quenched by the addition of 200ml water. Heptanes (340ml) were added and the phases were separated.
  • AT 30 - 50°C/200 - 120 mbar
  • To the distillation residue 290ml i-propylacetate followed by 130ml water were added.
  • the phases were separated and the organic phase was washed with 200ml 1 M NaHC0 3 solution in water, followed by a mixture of 200ml demineralised water and 20ml brine.
  • Example 1 Synthesis of 4- ⁇ 1-[(E)-4-Cvclohexyl-3-trifluoromethyl-benzyloxy-iminol-ethyl ⁇ -2-ethyl- benzaldehvde

Abstract

This invention relates to novel processes for synthesizing N-(4-cyclohexyl-3-trifluoromethyl-benzyloxy)-acetimidic acid ethyl ester and to the compound of formula I and other intermediates that are used in such processes.

Description

PROCESS FOR PREPARING N-(4-CYCLOHEXYL-3-TRIFLUOROMETHYL-BENZYLOXY)-
ACETIMIDIC ACID ETHYL ESTER
This invention relates to novel processes for synthesizing N-(4-cyclohexyl-3- trifluoromethyl-benzyloxy)-acetimidic acid ethyl ester and to intermediates that are used in such processes.
Background of the Invention
The compound N-(4-cyclohexyl-3-trifluoromethyl-benzyloxy)-acetimidic acid ethyl ester is an intermediate in the synthesis of the pharmaceutically active compound 1 -{4-[1-(4-cyclohexyl- 3-trifluoromethyl-benzyloxyimino)-ethyl-benxyl}-azetidine-3-carboxylic acid ("Compound A"). Compound A is a sphingosine-1 -phosphate ("S1 P") modulator that is useful for the treatment of immunological disorders, e.g., multiple sclerosis. Compound A, methods of synthesizing Compound A and methods of treating various disorders using Compound A are referred to in United States Patent 7,939,519, which issued on May 10, 201 1 . This patent is incorporated herein by reference in its entirety.
Summary of the Invention nvention relates to the compound having the formula
Figure imgf000003_0001
and the chemical name N-(4-Cyclohexyl-3-trifluoromethyl-benzyloxy)-acetimidic acid ethyl ester. This compound is an intermediate in the synthesis of Compound A.
This invention also relates to the compound having the formula
Figure imgf000004_0001
This compound is useful as an intermediate in the syntheses of both the compound of formula I and Compound A.
This invention also relates to compounds of the formula
Figure imgf000004_0002
wherein X1 is bromo, chloro, iodo or fluoro, preferably bromo. These compounds are useful as intermediates in the syntheses of both Compound A and the compound of formula I.
This invention also relates to the compound of formula
Figure imgf000004_0003
This compound is useful as an intermediate in the syntheses of both Compound A and the compound of formula I.
This invention also relates to the compound of formula
Figure imgf000005_0001
This compound is useful as an intermediate in the syntheses of both the compound of formula I and Compound A.
This invention also relates to the compound of formula
Figure imgf000005_0002
This compound is useful as an intermediate in the syntheses of both Compound A and the compound of formula I.
This invention also relates to the compound of formula
Figure imgf000006_0001
This compound is useful as an intermediate in the syntheses of both Compound A and the compound of formula I.
This invention also relates to the compound of formula
Figure imgf000006_0002
This compound is useful as an intermediate in the synthesis of Compound A from the compound of formula I.
This invention also relates to a process for preparing the compound of formula I, as described above, comprising reacting a compound having the formula
Figure imgf000007_0001
wherein X2 is bromo, chloro, iodo, mesylate, tosylate, brosylate, triflate or another suitable leaving group, preferably bromo, with the compound of formula
Figure imgf000007_0002
wherein Et is ethyl, in the presence of: (i) a strong base, preferably sodium hydride or potassium t-butoxide or, alternatively, a weaker base such as potassium carbonate or sodium carbonate; and (ii) a catalytic amount of 4-dimethylamino pyridine.
This invention also relates to the above method for preparing the compound of formula I from a compound of the formula IX, wherein the starting material of formula IX is prepared by a process comprising:
(a) reacting a compound of the formula
Figure imgf000008_0001
wherein X is bromo or iodo, preferably bromo, with an appropriate Grignard reagent (preferably, when X is bromo, i-propylmagnesiumchloride lithium chloride complex) and cyclohexanone to form the compound of formula
Figure imgf000008_0002
(b) reacting the compound of formula III with a strong acid, preferably sulfuric acid, to form the compound of formula
Figure imgf000008_0003
(c) subjecting the compound of formula IV to catalytic hydrogenation to form the compound of formula
Figure imgf000009_0001
(d) converting the compound of formula V into a compound of the formula
Figure imgf000009_0002
wherein X1 is bromo, chloro, iodo or fluoro, preferably bromo, by reacting the compound of formula V with 1 ,3-dibromyl-5,5-diethylhydantoin when X1 is bromo, or with the appropriate analogous compound when X1 is chloro, fluoro or iodo, in the presence of an acid, preferably trifluoroacetic acid or a mixture of sulfuric acid and trifluoroacetic acid;
(e) reacting the compound of formula VI with an appropriate Grignard reagent, preferably a butyl lithium butylmagnesium chloride complex, and carbon dioxide to form the compound of formula
Figure imgf000010_0001
(f) reducing the compound of formula VII, preferably using lithium aluminum hydride, to form the compound of formula
Figure imgf000010_0002
and
(g) subjecting the compound of formula VIII to a reaction that replaces the hydroxy group of formula VIII a leaving group, preferably by: (i) reacting the compound of formula VIII with the appropriate compound of the formula HX2, wherein X2 is defined as it is for formula IX above, to form a compound of the formula IX wherein X2 is chloro, bromo or iodo; or (ii) reacting the compound of formula VIII with the mesyl chloride, trifluoromesyl chloride or tosyl chloride to form a compound of the formula IX wherein X2 is mesylate, triflate or tosylate.
This invention also relates to the above method for preparing a compound of the formula I from a compound of the formula IX, as described above, wherein the starting material of formula IX is prepared by a process comprising:
(a) reacting a compound of the formula
Figure imgf000011_0001
wherein X4 is bromo, chloro or iodo, with the compound of formula
Figure imgf000011_0002
in the presence of a palladium catalyst, preferably palladium acetate, a phosphine, preferably triphenylphosphine, and a base, preferably, sodium methylate, to form the compound of formula
Figure imgf000011_0003
(b) subjecting the compound of formula XIII to catalytic hydrogenation to form the compound of formula
Figure imgf000012_0001
(c) subjecting the compound of formula XIV to radical bromination, preferably via reaction with N-bromosuccinimide, or radical chlorination, preferably via reaction with N- chlorosuccinimide, to yield a compound of the formula IX wherein X2 is bromo or chloro, respectively.
This invention also relates to a process for preparing the compound of formula I, as described above, from a compound of formula IX, wherein the starting material of formula IX is prepared by a process comprising:
(a) reducing a compound of the formula
Figure imgf000012_0002
wherein X5 is chloro, bromo or iodo, to form the corresponding compound of formula
Figure imgf000013_0001
wherein X5 is chloro, bromo or iodo;
(b) reacting the resulting compound of formula XVI with the compound of formula
Figure imgf000013_0002
in the presence of a palladium catalyst and a base, preferably in the presence of bistriphenylphosphinepalladiumdichloride and either potassium carbonate or sodium methylate, to form the compound of formula
Figure imgf000013_0003
(c) subjecting the compound of formula XVII to catalytic hydrogenation to form the compound of formula
Figure imgf000014_0001
and
(d) subjecting the compound of formula XVIII to a reaction that replaces the hydroxy group of formula VIII with a leaving group, preferably by: (i) when X2 in formula IX is chloro, fluoro or iodo, reacting the compound of formula VIII with the appropriate compound of the formula HX2, wherein X2 is defined as it is for formula IX; or (ii) when X2 in formula IX is mesylate, triflate or tosylate, reacting the compound of formula VIII with mesyl chloride, trifluoromesyl chloride or tosyl chloride, respectively.
This invention also relates to the process for forming the compound of formula I from a compound of the formula IX, as described above, wherein the starting material of formula IX is prepared by a process comprising:
(a) reacting a compound of the formula
Figure imgf000014_0002
wherein X5 is chloro, bromo or iodo, with the compound of formula
Figure imgf000015_0001
in the presence of a palladium catalyst and a base, preferably in the presence of bistriphenylphosphinepalladiumdichloride and either potassium carbonate or sodium methylate, to form the compound of formula
Figure imgf000015_0002
(b) subjecting the compound of formula XIX to catalytic hydrogenation to form the compound of formula
Figure imgf000015_0003
(c) reducing the compound of formula VII, preferably using lithium aluminum hydride, to form the compound of formula
Figure imgf000016_0001
and
(d) subjecting the compound of formula VIII to a reaction that replaces the hydroxy group of formula VIII a leaving group, preferably by: (i) when X2 in formula IX is chloro, bromo or iodo, reacting the compound of formula VIII with the appropriate compound of the formula HX2, wherein X2 is defined as it is for formula IX; or (ii) when X2 in formula IX is mesylate, triflate or tosylate or brosylate, reacting the compound of formula VIII with mesyl chloride, trifluoromesyl chloride, tosyl chloride or brosyl chloride, respectively.
Detailed Description of the Invention
In the discussion and reaction schemes that follow, X, X1, X2, X3, X4 and X5 are defined as they are defined above.
The compounds and processes of this invention are depicted below in reaction Schemes I - V.
Figure imgf000017_0001
Figure imgf000018_0001
Figure imgf000019_0001
Figure imgf000020_0001
Figure imgf000021_0001
Figure imgf000022_0001
Scheme 1 illustrates a method of synthesizing the compound of formula I from a compound of the formula IX, wherein the compound of formula IX is prepared by a seven step process starting with a compound of formula II. This method is advantageous in that it allows for the large scale production of the fragment of Compound A that is provided by the compound of formula I. Referring to Scheme I, a compound of the formula II, wherein X is bromo, chloro or iodo, preferably bromo, is reacted with an appropriate Grignard reagent, preferably an i- propylmagnesium chloride - lithium chloride complex, and cyclohexanone to form the compound of formula III. (When X is chloro, the Grignard compound is preferably formed by reaction with metallic magnesium, while, when X is iodo, the Grignard compound is preferably formed by an exchange with i-propylmagnesium chloride). This reaction is carried out in a solvent such as diethyl ether, tetrahydrofuran (THF), or an alkane such as hexane or heptane, or a mixture of two or more of the foregoing solvents, preferably a mixture of heptane and THF, at a temperature from about -20°C to about 30°C, preferably from about 5°C to about 10°C. The compound of formula III is then reacted, preferably in situ, with a strong acid such as sulfuric acid or phosphoric acid, preferably sulfuric acid, at an internal temperature (IT) from about 10°C to about 50°C, preferably from about 20°C to about 25°C, to form the compound of formula IV, which is then subjected to catalytic hydrogenation, using methods well known to those of skill in the art (e.g., palladium on carbon catalyst in a methanol solvent at a temperature from about 20°C to about 50°C and a pressure of about 2 - 20 bar, to produce the compound of formula V. The catalytic hydrogenation is also preferably conducted in situ.
Bromination of the compound of formula V, preferably in situ, at a temperature from about -10°C to about 20°C, preferably from about 0°C to about 5°C, yields the compound of formula VI wherein X1 is bromo. This bromination can be accomplished by reacting the compound of formula V with 1 ,3-dibromo-5,5-dimethylhydantoin or N-bromosuccinimide in an acid such as sulfuric acid, trifluoroacetic acid or a mixture of sulfuric and trifluoroacetic acids, at a temperature from about -10°C to about 5°C, preferably from about 0°C to about 5°C. The resulting halogenated compound of formula VI can then be converted into the corresponding carboxylic acid of formula VII by reacting it, preferably in situ, with an appropriate Grignard reagent (preferably a butyl lithium butyl magnesium chloride complex or a butyl lithium i- propylmagnesiumchloride complex) and carbon dioxide. Conducting this halogenation reaction with the appropriate analogous reagents will yield the corresponding compounds of formula VI wherein X is chloro, fluoro or iodo. The carbon dioxide is preferably bubbled through the reaction mixture. Suitable temperatures for this reaction range from about -20°C to about 20°C, preferably from about -5°C to about 5°C. Suitable solvents include diethyl ether, THF, methyltetrahydrofuran and alkanes such as heptane or hexane, with THF being preferred. Alternatively, if this reaction is conducted with dimethylformamide being added to the reaction mixture, the aldehyde (VIIA) corresponding to the carboxylic acid of formula VII is formed. This aldehyde is a liquid at room temperature, making purification of the aldehyde by crystallization impossible. Therefore, when the aldehyde is formed and carried forward in the process, as described below, impurities from the preceding steps, including the unwanted regioisomers of compound IV, will be carried through to the formation of the compound of formula I.
Reduction of the compound of formula VII, VIIA or VIII yields the compound of formula VIII. This reduction can be accomplished using a number of reducing agents well known to those of skill in the art (e.g., borane tetrahdrofurane complex, sodium borohydride/aluminum trichloride, aluminum hydride, lithium trimethoxyborohydride or lithium aluminum hydride). Lithium aluminum hydride is preferred. This reaction is generally carried out at a temperature from about -10°C to about 60°C, preferably from about 20°C to about 50°C. Suitable solvents include ethers (e.g., diethyl ether, dipropyl ether or THF), toluene or alkanes (e.g., heptane, hexane or cyclohexane), or a mixture one or more of the foregoing solvents. A miixture of toluene and THF is preferred.
The compound of formula VIII can be converted into the desired compound of formula IX wherein the hydroxide group is replaced with a leaving group such as bromine, chlorine, mesylate, tosylate, trilate, brosylate, phosphonate or another suitable leaving group. Leaving groups and methods of adding them to organic compounds are well known to those of skill in the art. (See Wuts, Peter G. M. and Greene, Theodore W., Greene's Protective Groups in Organic Synthesis, 4th Edition, Wiley, 2006, Print ISBN: 978-0-471-69754-1 , Online ISBN: 9780470053485). Bromine is a preferred leaving group. Bromine, chlorine and iodine can be added by reacting the compound of formula VIII with hydrogen bromide, hydrogen chloride, or hydrogen iodide, respectively. This reaction is generally carried out in a solvent such as acetic acid, acetic anhydride, or sulfuric acid, preferably a mixture of acetic acid and acetic anhydride, at a temperature from about 0°C to about 60°C, preferably from about 20°C to about 30°C. Mesylate, triflate, tosylate and brosylate groups can be added by reacting the compound of formula VIII with, respectively, mesyl chloride, trifluoromesyl chloride, tosyl chloride and brosyl chloride in a solvent, e.g., an ether such as diethyl ether, dipropyl ether or THF, toluene or an alkane such as heptane, hexane or cyclohexane, or a mixture of one or more of the foregoing solvents, with a mixture of toluene and THF being preferred, at a temperature from about -10°C to about 60°C, preferably from about 0°C to about 20°C, in the presence of a base such as triethylamine, Ν,Ν-diisopropylethylamine, or pyridine. Alternatively, this reaction can be conducted in a two phase system using an aqueous base such as sodium hydroxide, sodium carbonate, potassium hydroxide or potassium carbonate, and an organic solvent such as toluene, methylene chloride or alkanes such as heptane, hexane or cyclohexane, or a mixture thereof, with toluene being preferred.
The resulting compound of formula IX can be converted into the compound of formula I by reacting it with the compound of formula X
Figure imgf000025_0001
wherein Et is ethyl, in the presence of a strong base such as sodium hydride or potassium t- butoxide, lithium diisopropylamide, or potassium, lithium or sodium hexamethyldisilazide, preferably, sodium hydride or potassium t-butoxide, in a reaction inert solvent such as dimthylformamide (DMF), N-methylpyrrolidone (NMP), THF, methyltetrahydrofurane, toluene, an alkane such as hexane or heptane, a dialkyl ether such as ethyl ether, diiosopropylether, t- butylmethyl ether or methylcyclopentylether, or a mixture of two or more of the foregoing solvents, preferably, THF, at a temperature from about -29°C to about 40°C, preferably from about 0°C to about 10°C. Alternatively, the above reaction can be carried in the presence of a weaker base such as potassium carbonate, sodium carbonate, and a catalytic amount of 4- dimethylaminopyridine (DMAP), at the temperatures indicated immediately above, in a solvent such as acetone, methylethylketone, or cyclohexanone, preferably acetone.
Scheme 2 provides an alternate method of synthesizing the compound of formula IX. This process, which involves only three steps, is also useful for large scale production. Referring to Scheme 2, the compound of formula XI, wherein X4 is bromo, chloro or iodo, and the boronic acid of formula XII are subjected to a Suzuki Coupling reaction. This reaction is generally conducted in the presence of a palladium catalyst such as tetrakis(triphenylphoshine)palladium(0) or a mixture of a palladium (II) salt (e.g., palladium dichloride, palladium diacetate, or bistriphenylphosphinepalladium dichloride) and a phosphine (e.g., triphenylphosphine, tri-t-butylphosphine or tricyclohexylphosphine), and a base such as sodium methylate, potassium carbonate, cesium carbonate, or potassium t-butoxide, preferably sodium methylate, at a temperature from about 10°C to about 140°C, preferably from about 90°C to about 1 10°C. Suitable solvents for this reaction include dimethylformamide (DMF), dioxane, alcohols such as ethanol, methanol or i-propanol, toluene and esters such as ethylacetate and i-propylacetate. Methanol is preferred. The resulting compound of formula XIII is then subjected to catalytic hydrogenation, using methods well known to those of skill in the art (e.g., palladium on carbon catalyst in an acetic acid solvent at about 25°C and a pressure of about 1 - 20 atm) to produce the compound of formula XIV.
Conversion of the compound of formula XIV to the desired compound of formula IX is accomplished by subjecting the compound of formula XIV to a halogenation reaction. The halogenation can be via a radical bromination or radical chlorination reaction, to produce a compound of the formula IX wherein X2 is, respectively, chloro or bromo. Preferably, the reaction is a radical bromination, which is carried out by reacting the compound of formula XIV with N-bromosuccinimide, bromine, or 1 ,3-dimthyl-2,5-dibromohydantoine and a radical starter such as azoisobutyronitrile, preferably, N-bromosuccinimide, in a halogenated solvent such as dichloromethane or chlorobenzene, acetonitrile, i-ppropylacetate, or an alkane such as hexane, heptane or cyclohexane, preferably acetonitrile. The reaction temperature can range from about -20°C to about 50°C, and is preferably about 20°C. Radical chlorination can be carried out under similar conditions, using suitable chlorinated reactants such as N-chlorosuccinimide or chlorine, preferably N-chlorosuccinimide.
Scheme 3 provides another alternate method of synthesizing compounds of the formula IX. This process, which involves only four steps, is also useful for large scale production. Referring to Scheme 3, a compound of the formula XV, wherein X5 is chloro, bromo or iodo, is reacted with a strong reducing agent (e.g., borane tetrahdrofurane complex, sodium borohydride/aluminum trichloride, aluminum hydride, lithium trimethoxyborohydride or lithium aluminum hydride), preferably lithium aluminum hydride, to form the corresponding compound of formula XVI wherein X5 is, respectively, chloro, bromo or iodo. This reaction is generally carried out at a temperature from about -10°C to about 60°C, preferably from about 20°C to about 50°C. Suitable solvents include ethers such as diethyl ether, dipropyl ether or THF, toluene and alkanes such as heptane, hexane or cyclohexane, or a mixture thereof, with a mixture of toluene and THF being preferred. A Suzuki Coupling of the resulting compound of formula XVI with the boronic acid of formula XII, using conditions well known to those of skill in the art and referred to above in the discussion of Scheme 2, yields the compound of formula XVII. The compound of formula XVII can be converted into the compound of formula VIII via catalytic hydrogenation, using conditions well known to those of skill in the art (e.g., palladium on carbon catalyst in an acetic acid solvent at about 25°C and a pressure of about 1 - 20 atm). The conversion of the compound of formula VIII to the desired compound of formula IX can be accomplished as described above in the discussion of reaction Scheme I.
Scheme 4 illustrates another alternate method of synthesizing the compound of formula IX. This process also involves only four steps and is also useful for large scale production. Referring to Scheme 4, a compound of the formula XV, wherein X5 is chloro, bromo or iodo, and the boronic acid of formula XII are subjected to a Suzuki Coupling reaction, using conditions well known to those of skill in the art and referred to above in the discussion of Scheme 2, to form the compound of formula XIX. The compound of formula XIX is then subjected to catalytic hydrogenation, using conditions well known to those of skill in the art (e.g., palladium on carbon catalyst in an acetic acid solvent at about 25°C and a pressure of about 1 -20 atm), to produce the compound of formula VII, which can then be converted into the desired compound of formula IX via the compound of formula VIII, as described above in the discussion of the reaction chain VII→ VIII → IX in Scheme 1 .
A process by which Compound A can by synthesized from the compound of formula I is depicted in Scheme 5. Referring to Scheme 5, a solution of the compound of formula I in a solvent such as methanol, propanol or i-propanol and at a temperature from about -20°C to about 40°C, preferably at about 20°C, is treated with hydrochloric acid or sulfuric acid, preferably hydrochloric acid, to generate the oxime of formula XX, which is then reacted with compound of formula XXI to form the compound of formula XXII. The reaction of the compounds of formulas XX and XXI is generally conducted in an alcoholic solvent such as methanol, ethanol, isopropanol, or butanol. Methanol is preferred. Suitable reaction temperatures can range from about 0°C to about 60°C, with the preferred temperature being from about 20°C to about 40°C. The resulting compound of formula XXII is then dissolved in a solvent such as toluene, acetonitrile, methylene chloride, or alkanes such as hexane, heptanes or cyclohexane, or mixture of two or more of the foregoing solvents, preferably a mixture of toluene and ethyl acetate, and oxidized to form the compound of formula XXIII by the addition of an aqueous solution of potassium bromide and potassium bicarbonate and a catalytic amount of TEMPO (2,2,6,6-tetramethylpiperidine 1-oxyl) or poly[[6-[(1 , 1 ,3,3-tetramnethylbutyl)amino]- 1 ,3,5-triazine-2,4-diyl][(2,2,6,6-tetramethyl-1-oxy-4-piperidinyl)imino]-1 ,6-hexanediyl[(2,2,6,6- tetramethyl-1-oxy-4-piperidinyl)imino]]) (PIPO), followed by an aqueous solution of sodium hypochlorite. This reaction is generally conducted at a temperature from about -20°C to about 50°C, with the preferred temperature being from about 10°C to about 20°C. Alternatively, the compound of formula XXII in a solution of heptanes can be oxidized to form the compound of formula XXIII by the addition of manganese dioxide.
Reductive amination of the compound of formula XXIII, using methods well known to those of skill in the art, preferably with azetidine-3-carboxylic acid and sodium triacetoxyborohydride in methanol, followed by salt formation using methods well known to those of skill in the art, e.g., with fumaric acid in ethanol, followed by recrystallization from acetone/water, yeilds the hemifumarate salt of Compound A.
Experimental Examples
The following experimental examples illustrate the processes of the present invention and are not intended to limit the scope of such invention.
Example 1 : Synthesis of 1 -Cvclohex-1-enyl-2-trifluoromethyl-benzene
200ml i-Propylmagnesiumchlorid-LiCI complex 1.3M in THF were placed in a dry reactor at room temperature (RT) under Argon and cooled to IT = 5 - 10°C. Then 27.5ml 2- Brombenzotrifluorid was added within 1 hour (h) keeping IT at 5 - 10°C. The resulting mixture was stirred for 1 h at IT = 5 - 10°C. Then a solvent change from THF to heptanes was performed by distilling off THF while adding 120ml heptanes, keeping the volume of the reaction constant. To the obtained suspension, 23.1 ml Cyclohexanone was added within 1 h keeping IT at 15 - 25°C. The resulting emulsion was stirred at IT = 15 - 25°C for 1 -2h. After completion the reaction was quenched by the addition of 147g H2S04 10% at IT = 20 - 30°C. The phases were separated, the aqueous phase extracted with 14.2ml heptanes and the combined organic phases were washed with 13.5ml water. The organic phase was concentrated to a volume of 120ml and 42.1 g H2S04 90% were added within 1 h keeping IT at 20 - 25°C. The resulting mixture is stirred at high speed until the conversion from compound III to compound IV is complete. Then the phases were separated, the sulfuric acid phase extracted with 10ml heptanes. To the combined organic phases 1.46g Sodium acetate, 1 g Silicagel , 1 g charcoal and 1 ml Water were added. The mixture was filtrated over a nutsch filter covered with cellflock and the filtrate was evaporated to dryness giving 35.4g of 1 -Cyclohex-1- enyl-2-trifluoromethyl-benzene which was used without further purification for the synthesis of 1-Cyclohexyl-2-trifluoromethyl-benzene 1H-NMR (400MHz, DMSO-d6): δ 1 .5-1 .7(4H,m), 2.1-2.2(4H,m), 5.51 (1 H,m), 7.29(1 H,d), 7.44(1 H,t), 7.59(1 H,t), 7.68(1 H,d) MS:(ES"): 226 (M+)
Example 2: Synthesis of 1 -Cvclohexyl-2-trifluoromethyl-benzene
In a hydrogenation reactor 8.45g 1-Cyclohexyl-2-trifluoromethyl-benzene were dissolved in 42ml methanol. 1 .33g Palladium 10% on Charcoal water wet was added and the reaction mixture hydrogenated with hydrogen gas at IT = 40°C and 1 -5 Bar until the uptake of hydrogen stopped. After filtration over Hyflo, the filtrate was evaporated to dryness and degassed. Heptanes (40 ml) were added and the mixture was evaporated to dryness and degassed again. This gave 7.64g 1-cyclohexyl-2-trifluoromethyl-benzene as a slightly turbid yellow oil which was used without further purification for the synthesis of 4-bromo-1-cyclohexyl-2-trifluoromethyl- benzene.
1H-NMR (400MHz, CDCI3): δ 1.35-1 .9(1 OH, m), 2.85-3(1 h,m)7.2-7.3(1 H,m)7.4-7.5(2h,m), 7.55 - 7.65(1 H,m).
Example 3: Synthesis of 4-Bromo-1-cvclohexyl-2-trifluoromethyl-benzene
1-Cyclohexyl-2-trifluoromethyl-benzene (38.8g ) was dissolved in 126.4 trifluoroacetic acid at 20-25°C. Then the solution was cooled to IT = 0-5°C and 17.19g H2S04 (ca 96%) were added. To the resulting orange suspension 26.73g 1 ,3-dibromo-5,5-dimethylhydantoin were added in 6 portions within 1 -2h at IT = 0-5°C. Thirty minutes after the last addition, an in process control was performed and more 1 ,3-dibromo-5,5-dimethylhydantoin was added on an as needed basis. When the bromination was complete, 67.5g heptanes were added and the mixture was stirred for 5-10 minutes (min.) followed by phase separation at IT = 20 - 25°C. The lower inorganic phase was extracted a second time with 33.8ml heptanes. The combined organic phases were extracted with 57.85g 10% Na-hydrogensulfite in water followed by 55.4g 2N NaOH and three times 41 g water. Charcoal (0.61 g ) was added to the organic phase and the mixture was stirred 1 h at RT. After filtration, the filtrate was dried by isotropic distillation and evaporated to dryness. This gave 49.6g of 4-bromo-1-cyclohexyl-2-trifluoromethyl-benzene as a yellow oil, which was used without further purification for the synthesis of 4-cyclohexyl-3-trifluoromethyl-benzoic acid.
1H-NMR (400MHz, DMSO-d6): δ 1.2-1 .9(1 OH, m), 2.76(1 H,T), 7.55-7.61 (1 H,d), 7.76.7.85(2H,m) Example 4: Synthesis of 4-Cvclohexyl-3-trifluoromethyl-benzoic acid
In a dry vessel, 61.4g 4-bromo-1-cyclohexyl-2-trifluoromethyl-benzene were dissolved in 230ml tetrahydrofurane under nitrogen. i-Propylmagnesiumchloride (2M, 36.1 ml) in tetrahydrfuran (THF) were added within 15 - 30 min. Then the reaction mixture was cooled to IT = -5 - +5°C and 88ml 1.6M butyllithium in hexane were added from an addition funnel keeping IT = -5 - +5°C within 1-2h. To this solution 17.6g C02 were added within 1-2h at IT = -5 to +5°C. When the reaction was complete, the reaction was quenched by the drop wise addition of 160ml 2M H2S04, keeping IT at -5- 20°C. The phases were separated and the organic phase was washed with 2 times 100ml water and concentrated to a volume of approx. (approximately) 160ml. A solvent change to toluene was performed. The volume of the toluene solution was then adjusted to about 180ml and heated until a clear solution was obtained. Upon cooling to 0°C, 4-cyclohexyl-3- trifluoromethyl-benzoic acid crystallized out and was isolated by filtration followed by drying in a vacuum oven at 60°C over night. This gave 4-cyclohexyl-3-trifluoromethyl-benzoic acid as a white crystalline solid with a purity of >99%(F) by HPLC and a mp. of 206.7 - 208°C. 1H-NMR (400MHz, DMSO-d6): δ 1.2-1.8 (10H,m), 2.85(1 H,m), 7.7-8.1 (3H,m), 13.31 (1 H, s) MS:(ES"): 271 (M-1 ).
Example 5: Synthesis of 4-Cvclohexyl-3-trifluoromethyl-phenyl)-methanol
4-Cyclohexyl-3-trifluoromethyl-benzoic acid (1 19.8g) was suspended in 300ml toluene at 20 - 25°C. To this suspension 120ml 3.5M LiAIH4 in toluene/THF was added, keeping IT at 20 - 50°C. When the reaction was completed, the reaction mixture was carefully added to a mixture of 420ml water and 1 17ml 96% H2S04 keeping the internal temperature at 15 - 25 °C. Then the phases were separated and the aqueous phase was washed with 40ml toluene. The combined toluene phases were concentrated to a volume of 240ml. This solution of 4- cyclohexyl-3-trifluoromethyl-phenyl)-methanol was used, without purification, for the synthesis of 4-bromomethyl-1-cyclohexyl-2-trifluoro-methyl-benzene.
1H-NMR (400MHz, DMSO-d6): δ 1.2-1 .8(10H,m), 2.79(1 H,t), 4.52(2H,d), 5.30(1 H,t), 7.5- 7.6(3H,m) MS: 241 (MH-H20), 276 (M+NH4+)
Example 6: Synthesis of 4-Bromomethyl-1-cvclohexyl-2-trifluoro-methyl-benzene To the solution of 4-yclohexyl-3-trifluoromethyl-phenyl)-methanol from Example 6, 340ml HBr 5.7M in acetic acid were added at IT = 20 - 30 °C within 15 - 30 min. To the resulting emulsion 34ml acetic anhydride were added, keeping IT at 20 - 25°C. The reaction mixture was stirred at IT = 20 - 25 °C until the reaction was complete. The mixture was then quenched by the addition of 200ml water. Heptanes (340ml) were added and the phases were separated. The organic phase was washed with 240ml NaHC03 solution (ca 1 M) followed by 120ml water. Azeotropic drying and evaporation to dryness gave 4-bromomethyl-1-cyclohexyl-2-trifluoro- methyl-benzene as a clear yellow oil, which was used, without purification, for the synthesis of N- (4-cyclohexyl-3-trifluoromethylbenzy-loxy)-acetimidic acid ethyl ester
1H-NMR (400MHz, CDCI3): δ 1 .2-1 .8(10H,m), 2.93(1 H,t), 4.49 (2H,s), 7.44(1 H,d), 7.53(1 H,d), 7.62(1 H,d) MS:320,322 M+, 241 M-Br+
Example 7: Synthesis of N-(4-Cvclohexyl-3-trifluoromethylbenzyloxy)-acetimidic acid ethyl ester
4-Bromomethyl-1-cyclohexyl-2-trifluoro-methyl-benzene (68.25g) and 50g N-hydroxy-acetimidic acid ethyl ester as a 50% solution in CH2CI2 were dissolved in 350ml acetone. To this solution 1.17g 4-dimethylaminopyridine and 139g potassium carbonate were added. This suspension was stirred at IT = 50 - 52°C until the reaction was complete. Then the mixture was cooled to 20 - 25°C, filtrated and a solvent was changed to t-butylmethylether. The solution in t- butylmethylether was adjusted to a volume of 400ml and extracted with 150ml water 2X, followed by 100ml brine. Evaporation to dryness gave 66.7g of N-(4-cyclohexyl-3- trifluoromethylbenzy-loxy)-acetimidic acid ethyl ester as a yellow oil, which was used, without purification, for the synthesis of 1-(3-Ethyl-4-hydroxymethyl-phenyl)-ethanone 0-(4-cyclohexyl-3- trifluoromethyl-benzyl)-oxime
1H-NMR (400MHz, DMSO-d6): δ 1 .26 (3H,t), 1.35 - 1.9(10H,m), 1.96(3H,s), 2.93(1 H,m), 3.99- 4.03(2H,q), 4.92(2H,s), 7.4-7.6(3H,m), MS(ES+) : 344(MH+)
Example 8: Synthesis of N-(4-Cvclohexyl-3-trifluoromethylbenzyloxy)-acetimidic acid ethyl ester
In a dry vessel, 39.7g N-Hydroxy-acetimidic acid ethyl ester as a 50% solution in tetrahydrofurane were added to 200ml of tetrahydrofurane. To this solution 123.4 g of a 20%solution of potassium t-butylate in THF was added within 1 h, keeping IT at 0 - 5 °C. After stirring this solution for 2h ( IT at 0 - 5 °C), a solution of 70g 4-bromomethyl-1-cyclohexyl-2-trifluoro-methyl-benzene in 70ml tetrahydrofurane was added within 2h, keeping IT at 0 - 5 °C. After completion of the reaction, the mixture was quenched by the addition of 200ml ethylacetate and 200ml water. The phases are separated and the organic phase was washed twice with 200ml NaCI solution (2% in water). Evaporation, addition of 200ml Ethylacetate and evaporation to dryness gave 66.1 g N-(4-cyclohexyl-3-trifluoromethylbenzyloxy)-acetimidic acid ethyl ester as a yellow oil, which was used without further purification for the synthesis of 1-(3-Ethyl-4-hydroxymethyl- phenyl)-ethanone 0-(4-cyclohexyl-3-trifluoromethyl-benzyl)-oxime.
1H-NMR (400MHz, DMSO-d6): δ 1 .26 (3H,t), 1.35 - 1.9(10H,m), 1.96(3H,s), 2.93(1 H,m), 3.99- 4.03(2H,q), 4.92(2H,s), 7.4-7.6(3H,m), MS(ES+) : 344(MH+)
Example 9: Synthesis of 1-(3-Ethyl-4-hvdroxymethyl-phenyl)-ethanone 0-(4-cvclohexyl-3-trifluoro- methyl-benzvD-oxime
N-(4-Cyclohexyl-3-trifluoromethylbenzy-loxy)-acetimidic acid ethyl ester (42.9g ) was dissolved in 306ml methanol. To this 20.1 ml 36% HCI were added, keeping IT = 20 - 25°C. The mixture was stirred at IT = 20 - 25°C for 30 - 40 min. Then the pH was adjusted to 4.5 by the addition of ca 30ml triethylamine. Then 21 .4g 1-(3-ethyl-4-hydroxymethyl-phenyl)-ethanone dissolved in 87ml methanol were added at IT = 20 - 25°C within 5-10 min. The reaction mass was stirred at IT = 20 - 25 °C for 20 - 24h. During this time, the pH dropped to 0-1. After the reaction went to completion, the methanol was distilled off at AT = 30 - 50°C/200 - 120 mbar within 1 - 5h. To the distillation residue 290ml i-propylacetate followed by 130ml water were added. The phases were separated and the organic phase was washed with 200ml 1 M NaHC03 solution in water, followed by a mixture of 200ml demineralised water and 20ml brine. The organic phase was concentrated at the rotary evaporator (AT = 30 - 40°C/120 - 10mbar) to a volume of 100ml. The distillation residue was dissolved in 250ml toluene and again evaporated to dryness. This gave 57g 1-(3- ethyl-4-hydroxymethyl-phenyl)-ethanone 0-(4-cyclohexyl-3-trifluoro-methyl-benzyl)-oxime as a slightly yellow oil, which was used without further purification for the synthesis of 4-{1-[(E)-4- Cyclohexyl-3-trifluoromethyl-benzyloxy-imino]-ethyl}-2-ethyl-benzaldehyde.
Example 10: Synthesis of 4-{1-[(E)-4-Cvclohexyl-3-trifluoromethyl-benzyloxy-iminol-ethyl}-2-ethyl- benzaldehvde
1-(3-Ethyl-4-hydroxymethyl-phenyl)-ethanone 0-(4-cyclohexyl-3-trifluoro-methyl-benzyl)-oxime (45g ) was dissolved in 134 ml heptanes. To this solution 59.7g manganese dioxide were added in one portion and washed down with 43ml heptanes. The reaction mixture was stirred at IT = 50 - 55 °C until the reaction went to completion. Then it was filtrated over a Nutsche filter with CEFOK. The filtrate was evaporated to dryness and dissolved in 60ml i-propanol containing 2ml water by heating to reflux. Upon cooling to 0°C, 4-{1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxy- imino]-ethyl}-2-ethyl-benzaldehyde crystallized out and was isolated by filtration. Drying over night in a vacuum oven at 60°C gave 22g 4-{1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxy-imino]- ethyl}-2-ethyl-benzaldehyde as a white crystalline solid, which was further purified by crystallization from i-propanol containing 3% water.
1H-NMR (400MHz, DMSO-d6): δ 1 .20(3H,t), 1 .34(6H,m), 1.4-1 .8(10H,m), 2.28 (3H,s), 2.82(1 H,m)3.05(2H,q), 5.30(2H,s), 7.6-7.88(6H,m), 10.27(1 H,s) MS:(ES+):432 (M+1 )
Mp.:80.5 - 81.5°C.
Example 1 1 : Synthesis of 4-{1-[(E)-4-Cvclohexyl-3-trifluoromethyl-benzyloxy-iminol-ethyl}-2-ethyl- benzaldehvde
1-(3-Ethyl-4-hydroxymethyl-phenyl)-ethanone 0-(4-cyclohexyl-3-trifluoro-methyl-benzyl)-oxime (57g) was dissolved in 176ml toluene and 176ml ethylacetate. To this solution 183mg TEMPO, followed by 31.18g ca 25% KBr solution and 135.5g ca 14% KHC03 solution were added within 10 - 30min. The mixture was cooled to IT = 10 - 20 °C and 94g NaOCI solution 10.9% were added with intensive stirring at IT = 10 - 20° within 30 - 60 min. The reaction mixture was stirred for 30 min and, when an in process control showed complete conversion, quenched by the addition of 87g 10% Na-thiosulfate solution at IT = 20 - 25 °C. The phases were separated and then the organic phase was washed with 2X 100ml water. Then the organic phase was concentrated to a volume of 55 ml and 90ml i-Propanol containing 3% H20 (water) were added and the mixture was again distilled to a volume of 55ml. 90ml i-Propanol containing 3% H20 were added and the mixture was heated to IT = 60 - 65°C to obtain a clear solution. Upon cooling to 0°C, crude 4-{1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxy-imino]-ethyl}-2-ethyl- benzaldehyde crystallized out and was isolated by filtration. The wet cake was again recrystallized from 50ml i-propanol containing 3% water. After drying overnight in a vacuum oven at 40°C, 35.5g 4-{1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxy-imino]-ethyl}-2-ethyl-benzaldehyde was obtained as a slightly yellow powder.
1H-NMR (400MHz, DMSO-d6): δ 1.20(3H,t), 1.34(6H,m), 1 .4-1 .8(10H,m), 2.28 (3H,s), 2.82(1 H,m)3.05(2H,q), 5.30(2H,s), 7.6-7.88(6H,m), 10.27(1 H,s) MS:(ES+):432 (M+1 ) Example 12: Synthesis of 1-(4-{1-r(E)-4-Cvclohexyl-3-trifluoromethyl-benzyloxyiminol-ethyl}-2- ethyl-benzyl)-azetidine-3-carboxylic acid hemifumarate
4-{1 -[(E)-4-Cyclohexyl-3-trifluoromethyl-benzyloxy-imino]-ethyl}-2-ethyl-benzaldehyde (15g) and 4.93g azetidine-3-carboxylic acid were suspended in 260 ml methanol and stirred for 30 min at 20 - 25 °C. Then 13.97g sodium triacetoxyborohydride were added within 1-2 h in 8 portions of 1.75g at IT = 20-25°C. The reaction was stirred until an in process control showed complete conversion to 1 -(4-{1 -[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl}-2-ethyl-benzyl)- azetidine-3-carboxylic acid. Then methanol was distilled off to a volume of 50ml. 180ml ethyl acetate and 90ml water were added and the pH was adjusted to 6 by the addition of about 40ml 2M NaOH. The phases were separated and the organic phase was washed with 35ml water. The organic phase was distilled to a volume of 100ml; 100ml 100% ethanol were added and the organic phase was again distilled to a volume of 100ml. A second portion of 100ml 100% ethanol was added and the organic phase was again distilled to 100ml. Then 100ml 100% ethanol were added, together with 1 .5g charcoal and 1 .5g Hyflo. The resulting suspension was stirred for 30 min at 20 - 25 °C, filtrated and concentrated to a volume of 140ml. Then 10ml of a preheated (50°C) 3% solution of a fumaric acid in 100% ethanol was added at IT = 50°C . The solution was seeded with 1-(4-{1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl}-2- ethyl-benzyl)-azetidine-3-carboxylic acid hemifumarate, and after the crystallization has started, 90.1 g of a 3% solution of a fumaric acid in 100% ethanol was added within 30 min— 1 h at IT = 50°C. The suspension was slowly cooled to 20°C, filtrated and dried in a vacuum oven at 40°C overnight. This gave 15.34g 1-(4-{1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl}-2- ethyl-benzyl)-azetidine-3-carboxylic acid hemifumarate.
1H-NMR (400MHz, DMSO-d6): δ 1.14(3H,t), 1.25-1.85(10H,m), 2.2(3H,s), 2.6 - 2.7(2H,q), 2.75- 2.85(1 H,t), 3.17-3.28(3H,m), 3.38-3.46(2H,m), 3.6(2H,s), 5.21 (2H,s), 6.61 (1 H,s), 7.22-7.7 (6H,m)
Example 13: Synthesis of 4-Cvclohex-1-enyl-3-trifluoromethyl-benzoic acid
In pressure reactor 20g 4-bromo-3-(trifluoromethyl)benzoic acid, 9.37g cyclohexenylboronic acid, 0.52g bis(triphenylphosphine)palladium (II) chloride and 15.41 g potassium carbonate in 150ml methanol were carefully degassed and stirred under nitrogen at IT 95°C until the reaction went to completion (3-4h). Ethylacetate (250ml) and 200ml 0.1 N HCI were added to the reaction mixture at IT = 20 - 25°C. The phases were separated and the organic phase was washed with 2X 159 ml 10% NaCI in water. Then 5g charcoal were added to the organic phase, and the mixture is stirred for 30 min and filtrated. Evaporation to dryness gave 20.02g of an orange solid which contained ca 94% 4-cyclohex-1-enyl-3-trifluoromethyl-benzoic acid according to HPLC. This is used without further purification for the synthesis of 4-cyclohexyl-3- trifluoromethyl-benzoic acid
1H-NMR (400MHz, DMSO-d6): δ 1 .6-1 .8(4H,m), 2.1-2.3(41-1, m), 5.58(1 H,t), 7.48(1 H,d), 8.12- 8.17(2H,m) MS: 269.0799(M-H)"
Example 14: Synthesis of 4-Cvclohexyl-3-trifluoromethyl-benzoic acid
In a hydrogenation reactor, 18.0 g 4-cyclohex-1-enyl-3-trifluoromethyl-benzoic acid were dissolved in 150 ml methanol and 10% 7.1 g palladium on charcoal were added. After 15h hydrogenation at 4.5 bar/50°C the starting material was consumed. Filtration and evaporation to dryness gave 16g of a solid, which was recrystallized from 1 10ml toluene to give 12.9g 4- cyclohexyl-3-trifluoromethyl-benzoic acid, which, according to HPLC and 1H-NMR, was identical to the 4-cyclohexyl-3-trifluoromethyl-benzoic acid of Example 4.
Example 15: Synthesis of 1-Cvclohex-1-enyl-4-methyl-2-trifluoromethyl-benzene
In a pressure tube, 2.575 g 1-bromo-4-methyl-2-(trifluoromethyl)benzene, 1.839 g cyclohexenylboronic acid , 0.075 g Bis[Triphenylphosphin]Pdalladiumdichloride and 7.317 ml sodium methanolate were dissolved in 13ml methanol. This mixture was stirred at AT = 100 °C until the reaction was completed. The reaction mixture was cooled to 20 - 25 °C and evaporated to dryness. The residue was dissolved in a 2:1 mixture of heptanes and ethyl acetate. The solution was washed with aqueous NH4CI solution followed by aqueous K2C03 solution, dried over Na2S04, filtrated over a small pad of silica gel and evaporated to dryness. This gave 2.25g of 1-cyclohex-1-enyl-4-methyl-2-trifluoromethyl-benzene as colorless oil, which was used without further purification for the synthesis of 1-cyclohexyl-4-methyl-2-trifluoromethyl- benzene.
1H-NMR (400MHz, CDCI3): δ 1 .5-2.1 (8H,m), 2.28(3H,s), 5.45(1 H,s), 6.9-7.3(3H,m) Example 16: Synthesis of 1-Cvclohexyl-4-methyl-2-trifluoromethyl-benzene
In a hydrogenation reactor, 2.25g 1-cyclohex-1-enyl-4-methyl-2-trifluoromethyl-benzene was dissolved in 15ml methanol. Five percent Pd/C (0.399g, water wet), was added and the mixture was hydrogenated at IT= 60°C/5bar for 16h. After the hydrogenation went to completion, the reaction mixture was cooled to 20 - 25 °C, filtrated and evaporated to dryness. The residue was dissolved in heptanes, washed with water, dried over Na2S04 and filtrated over a small pad of Silica gel. Evaporation to dryness gave 2.27g 1-cyclohexyl-4-methyl-2-trifluoromethyl- benzene as a colorless oil, which was used without further purification for the synthesis of 4- bromomethyl-1-cyclohexyl-2-trifluoromethyl-benzene.
1H-NMR (400MHz, CDCI3): δ 1 .4-1 .95(10H,m), 2.38(3H,s), 2.9(1 H,m), 7.2-7.5 (3H,m)
Example 17: Synthesis of 4-Bromomethyl-1-cvclohexyl-2-trifluoromethyl-benzene
In a pressure tube, 100mg 1-cyclohexyl-4-methyl-2-trifluoromethyl-benzene was dissolved in 1.5ml heptanes and 75μΙ acetonitrile , 0.105g N-bromosuccinimide and 3.2mg 2,2'-azobis(2- methylpropionitrile) (AIBN) were added. This mixture was stirred over night at IT = 80 °C. After cooling to RT, water was added to the reaction mixture and the phases were separated. The aqueous phase was washed with cyclohexane, the combined organic phases were washed with water followed by brine and dried over Na2S04. Evaporation to dryness gave a yellow oil, the main component of which, according to HPLC and 1H-NMR, was identical to the 4- bromomethyl-1-cyclohexyl-2-trifluoromethyl-benzene from Example 6.

Claims

Claims
1. The compound of formula
Figure imgf000037_0001
2. A compound of the formula
Figure imgf000037_0002
wherein X1 is bromo, chloro or iodo.
3. The compound of formula
Figure imgf000038_0001
4. The compound of formula
Figure imgf000038_0002
5. The compound of formula
Figure imgf000038_0003
6. The compound of formula
Figure imgf000039_0001
7. The compound of formula
Figure imgf000039_0002
8. The compound of formula
Figure imgf000039_0003
9. The compound of formula
Figure imgf000040_0001
10. The compound of formula
Figure imgf000040_0002
11. A process for preparing the compound of claim 1, comprising reacting a compound of the formula
Figure imgf000040_0003
wherein X2 is bromo, chloro, iodo, mesylate, tosylate, triflate or another suitable leaving group, with the compound of formula
Figure imgf000041_0001
in the presence of a strong base.
12. A process according to claim 1 1 , wherein the base is sodium hydride and the process is conducted in the presence of a catalytic amount of 4-dimethylamino pyridine.
13. A process according to claim 1 1 , wherein X2 is bromo.
14. A process according to claim 1 1 wherein the starting material of formula IX is obtained by a process comprising:
(a) reacting a compound of the formula
Figure imgf000041_0002
wherein X is chloro, bromo, or iodo, with a Grignard reagent to form the compound of the formula
Figure imgf000041_0003
(b) reacting the compound of formula III with strong acid to form the compound of formula
Figure imgf000042_0001
(c) subjecting the compound of formula IV to catalytic hydration to form the compound of formula
Figure imgf000042_0002
(d) converting the compound of formula V into a compound of the formula
Figure imgf000042_0003
wherein X1 is bromo, chloro or iodo, by reacting the compound of formula V with 1 ,3-dibromyl- 5,5-diethylhydantoin when X1 in formula VI is bromo, or by reacting the compound of formula V with the appropriate analogous compound when X1 is chloro, fluoro or iodo, in the presence of an acid;
(e) reacting the compound of formula VI with a Grignard reagent and carbon dioxide to form the compound of formula
Figure imgf000043_0001
or, alternatively, when carrying out the above reaction of step "e", adding dimethylformamide to the Grignard reagent to form the corresponding aldehyde of formula
Figure imgf000043_0002
(f) reducing the compound of formula VII or VI IA to form the compound of formula
Figure imgf000044_0001
(g) reacting the compound of formula VIII with the appropriate compound of the formula HX2, wherein X2 is defined as it is for formula IX, to form the desired compound of formula IX.
15. A process according to claim 14, wherein, in step "a", X is chloro and the Grignard reagent is isopropylmagnesium chloride lithium chloride complex.
16. A process according to claim 14, wherein, in step "b", the acid is sulfuric acid.
17. A process according to claim 14, wherein, in step "d", X1 is bromo.
18. A process according to claim 14, wherein, in step "d", the acid is sulfuric acid, trifluoroacetic acid or a mixture of trifluoroacetic acid and sulfuric acid.
19. A process according to claim 14, wherein, in step "e", the Grignard reagent is a butyl lithium butylmagnesiumchloride complex or a butyl lithium i-propylmagnesiumchloride complex.
20. A process according to claim 14, wherein, wherein, in step "e", an aldehyde of formula VIIA is formed.
21 . A process according to claim 14, wherein, in step "f", the reducing agent is lithium aluminum hydride.
22. A process according to claim 1 1 , wherein the starting material of formula IX is obtained by a process comprising:
(a) reacting a compound of the formula
Figure imgf000045_0001
with the compound of formula
Figure imgf000045_0002
to form the compound of formula
Figure imgf000045_0003
(b) subjecting the compound of formula XIII to catalytic hydrogenation, to form the compound of formula
Figure imgf000046_0001
and
(c) subjecting the compound of formula XIV to radical bromination with N- bromosuccinamide, or to standard bromination with hydrobromic acid, to form the compound of formula IX wherein X2 is bromo, or, alternatively, reacting the compound of formula XIV with the appropriate compound of formula HX2, wherein X2 is defined as it is for formula IX, to form the desired compound of formula IX.
23. A process according to claim 22, wherein, in step "c", the compound of formula XIV is reacted with N-bromosuccinimide, bromine or 1 ,3-dimethyl-2,5-dibromohydantoine and a radical starter.
24. A process according to claim 22, wherein step "a" is conducted in the presence of a base, a phosphine and a palladium catalyst.
25. A process according to claim 24, wherein the palladium catalyst is palladium acetate and the base is sodium methylate and the phosphine is triphenylphosphine.
26. A process according to claim 22, wherein the reaction of step "a" is conducted in methanol.
27. A process according to claim 1 1 , wherein the starting material of formula IX is obtained by a process comprising:
(a) reducing the compound of formula
Figure imgf000047_0001
wherein X is chloro, bromo or iodo, to form the compound of formula
Figure imgf000047_0002
wherein X5 is defined as above,
(b) reacting the compound of formula XVI with the compound having the formula
Figure imgf000047_0003
to form the compound of formula
Figure imgf000048_0001
(c) subjecting the compound of formula XVII to catalytic hydrogenation to form the compound of formula
Figure imgf000048_0002
and
(d) reacting the compound of formula XVIII with the appropriate compound of the formula HX2, wherein X2 is defined as it is for formula IX, to form the desired compound of formula IX.
28. A process according to claim 27 wherein, in step "d", the compound of formula HX2 is hydrogen bromide.
29. A process according to claim 27 wherein, in step "a", the reducing agent used is lithium aluminum hydride.
30. A process according to claim 27 wherein X5 is bromo.
31 . A process according to claim 27 wherein the reaction of step "b" is carried out in the presence of a palladium catalyst and a phosphine.
32. A process according to claim 1 1 , wherein the starting material of formula IX is obtained by a process comprising:
(a) reacting a compound of the formula
Figure imgf000049_0001
wherein X5 is chloro, bromo or iodo, with the compound of formula
Figure imgf000049_0002
to form the compound of formula
Figure imgf000049_0003
(b) subjecting the compound of formula XIX to catalytic hydrogenation to form the compound of formula
Figure imgf000050_0001
(c) reducing the compound of formula VII to form the compound of formula
Figure imgf000050_0002
and
(d) reacting the compound of formula VIII with the appropriate compound of the formula HX2, wherein X2 is defined as it is for formula IX, to form the desired compound of formula IX.
33. A process according to claim 32, wherein, in step "c", the reducing agent is lithium aluminum hydride.
34. A process according to claim 32, wherein step "a" is carried out in the presence of a palladium catalyst and a phosphine.
35. A process according to claim 32, wherein step "a" is carried out in a methanol solvent.
36. A process according to claim 32, wherein X5 is bromo.
37. A process according to claim 1 1 , wherein the starting material of formula IX is obtained by a process comprising:
(a) reducing the compound of formula VII or VIIA
Figure imgf000051_0001
to form a compound of the formula
Figure imgf000051_0002
and
(b) reacting the compound of formula VIII with the appropriate compound of the formula HX2, wherein X2 is defined as it is for formula IX, to form the desired compound of formula IX.
38. A process according to claim 37, wherein, in step "a", the reducing agent is lithium aluminum hydride.
39. A process according to claim 37, wherein, in step "b", the compound of formula VIII is reacted with hydrogen bromide.
40. A process according to claim 37, wherein the solvent for step "b" is acetic acid or a mixture comprising acetic acid.
41 . A process according to claim 23 wherein the compound of formula XIV is reacted with N- bromosuccinimide and a radical starter which is azoisobutyronitrile
PCT/EP2013/052106 2012-02-03 2013-02-01 Process for preparing n-(4-cyclohexyl-3-trifluoromethyl-benzyloxy)-acetimidic acid ethyl ester WO2013113915A1 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
US14/376,143 US9604914B2 (en) 2012-02-03 2013-02-01 Process for preparing N-(4-cyclohexyl-3-trifluoromethyl-benzyloxy)-acetimidic acid ethyl ester
KR1020147024290A KR20140121469A (en) 2012-02-03 2013-02-01 Process for preparing n-(4-cyclohexyl-3-trifluoromethyl-benzyloxy)-acetimidic acid ethyl ester
CA2862375A CA2862375A1 (en) 2012-02-03 2013-02-01 Process for preparing n-(4-cyclohexyl-3-trifluoromethyl-benzyloxy)-acetimidic acid ethyl ester
CN201380007968.0A CN104105687B (en) 2012-02-03 2013-02-01 The method for preparing N (trifluoromethyl benzyloxy of 4 cyclohexyl 3) second imido acetoacetic ester
EP13702472.5A EP2809645A1 (en) 2012-02-03 2013-02-01 Process for preparing n-(4-cyclohexyl-3-trifluoromethyl-benzyloxy)-acetimidic acid ethyl ester
MX2014009352A MX350211B (en) 2012-02-03 2013-02-01 Process for preparing n-(4-cyclohexyl-3-trifluoromethyl-benzyloxy )-acetimidic acid ethyl ester.
AU2013214103A AU2013214103B2 (en) 2012-02-03 2013-02-01 Process for preparing N-(4-cyclohexyl-3-trifluoromethyl-benzyloxy)-acetimidic acid ethyl ester
JP2014555236A JP6209541B2 (en) 2012-02-03 2013-02-01 Method for producing N- (4-cyclohexyl-3-trifluoromethyl-benzyloxy) -acetimidic acid ethyl ester
RU2014135795A RU2014135795A (en) 2012-02-03 2013-02-01 METHOD FOR PRODUCING N- (4-CYCLOGEXYL-3-TRIFFORMETHYLBENZYLOXYL) ACETIMIDIC ACID ETHYL ETHER
BR112014018756A BR112014018756A8 (en) 2012-02-03 2013-02-01 PROCESS FOR PREPARING N-(4-CYCLO-HEXYL-3-TRIFLUOROMETHYL-BENZYLOXY)-ACETIMIDIC ACID ETHYL ESTER
IL233791A IL233791A0 (en) 2012-02-03 2014-07-24 Process for preparing n-(4-cyclohexyl-3-trifluoromethyl-benzyloxy)-acetimidic acid ethyl ester
IL249227A IL249227A0 (en) 2012-02-03 2016-11-27 Process for preparing n-(4-cyclohexyl-3-trifluoromethyl-benzyloxy)-acetimidic acid ethyl ester
US15/432,213 US20170166517A1 (en) 2012-02-03 2017-02-14 Process for Preparing N-(4-Cyclohexyl-3-trifluoromethyl-benzyloxy)-acetimidic Acid Ethyl Ester

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261594591P 2012-02-03 2012-02-03
US61/594,591 2012-02-03

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/376,143 A-371-Of-International US9604914B2 (en) 2012-02-03 2013-02-01 Process for preparing N-(4-cyclohexyl-3-trifluoromethyl-benzyloxy)-acetimidic acid ethyl ester
US15/432,213 Division US20170166517A1 (en) 2012-02-03 2017-02-14 Process for Preparing N-(4-Cyclohexyl-3-trifluoromethyl-benzyloxy)-acetimidic Acid Ethyl Ester

Publications (1)

Publication Number Publication Date
WO2013113915A1 true WO2013113915A1 (en) 2013-08-08

Family

ID=47633092

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2013/052106 WO2013113915A1 (en) 2012-02-03 2013-02-01 Process for preparing n-(4-cyclohexyl-3-trifluoromethyl-benzyloxy)-acetimidic acid ethyl ester

Country Status (12)

Country Link
US (2) US9604914B2 (en)
EP (1) EP2809645A1 (en)
JP (2) JP6209541B2 (en)
KR (1) KR20140121469A (en)
CN (1) CN104105687B (en)
AU (2) AU2013214103B2 (en)
BR (1) BR112014018756A8 (en)
CA (1) CA2862375A1 (en)
IL (2) IL233791A0 (en)
MX (1) MX350211B (en)
RU (1) RU2014135795A (en)
WO (1) WO2013113915A1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019013126A1 (en) 2017-07-13 2019-01-17 東レ・ファインケミカル株式会社 Production method for cycloalkyl(trifluoromethyl)benzene
WO2019064217A1 (en) 2017-09-29 2019-04-04 Novartis Ag Dosing regimen of siponimod
WO2019064212A1 (en) 2017-09-29 2019-04-04 Novartis Ag Dosing regimen of siponimod
WO2019064184A1 (en) * 2017-09-27 2019-04-04 Dr. Reddy's Laboratories Limited Process for preparation of siponimod, its salts and solid state forms thereof
WO2019144094A1 (en) 2018-01-22 2019-07-25 Teva Pharmaceuticals International Gmbh Crystalline siponimod fumaric acid and polymorphs thereof
WO2020161632A1 (en) * 2019-02-07 2020-08-13 Dr. Reddy’S Laboratories Limited Crystalline solid forms of siponimod
WO2020201172A1 (en) 2019-03-29 2020-10-08 Synthon B.V. Process for making siponimod and intermediate thereof
WO2021214717A1 (en) 2020-04-23 2021-10-28 Novartis Ag Dosing regimen for the use of siponimod for the treatment of acute respiratory distress syndrome
IT202000019897A1 (en) 2020-08-10 2022-02-10 Olon Spa PROCEDURE FOR THE PREPARATION OF A KEY INTERMEDIATE OF THE SIPONIMOD
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020173346A1 (en) * 2019-02-25 2020-09-03 广东东阳光药业有限公司 Method for preparing siponimod
EP4139282A2 (en) 2020-05-29 2023-03-01 Cipla Limited Methods for the preparation of sphingosine 1-phosphate receptor modulators and solid forms thereof
WO2022127863A1 (en) * 2020-12-16 2022-06-23 苏州晶云药物科技股份有限公司 Crystal forms of hemifumarate salt of carboxylic acid compound and preparation method therefor
CN112811995A (en) * 2021-01-14 2021-05-18 惠泽化学科技(濮阳)有限公司 Synthesis method of 4-substituent cyclohexanone liquid crystal intermediate
CN113896650A (en) * 2021-10-27 2022-01-07 成都科圣原医药科技有限公司 Synthesis method of siponimod intermediate
CN113880708B (en) * 2021-12-06 2022-03-18 南京桦冠生物技术有限公司 Preparation method of 4-cyclohexylbenzoic acid

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3452079A (en) * 1964-06-15 1969-06-24 Merck & Co Inc Acetic acid type compounds
WO2004103306A2 (en) * 2003-05-19 2004-12-02 Irm Llc Immunosuppressant compounds and compositions
WO2005082841A1 (en) * 2004-02-24 2005-09-09 Irm Llc Immunosuppressant compounds and compositions
US20070203100A1 (en) * 2004-02-24 2007-08-30 Irm Llc Immunosuppressant Compounds and Compositions
WO2008074820A1 (en) * 2006-12-21 2008-06-26 Glaxo Group Limited Oxadiazole derivatives as s1p1 receptor agonists
US20100113528A1 (en) * 2007-04-19 2010-05-06 Glaxo Group Limited Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1495793A (en) * 1965-10-08 1967-09-22 Merck & Co Inc Process for the manufacture of alpha- (lower alkyl) -phenylacetic acids from the corresponding ketones
DE2651083A1 (en) * 1976-11-09 1978-05-18 Hoechst Ag NEW O-ALKYLATED HYDROXYLAMINE, METHOD FOR THEIR PRODUCTION AND THEIR USE
US6596877B2 (en) * 2001-10-17 2003-07-22 Novartis Ag Accelerated process for preparing O-methyl phenols, N-methyl heteroaromatic compounds, and methylated aminophenols
PL1638551T3 (en) * 2003-05-19 2012-05-31 Irm Llc Immunosuppressant compounds and compositions
US20090324581A1 (en) * 2006-05-09 2009-12-31 Daiichi Sankyo Company Limited Heteroarylamide lower carboxylic acid derivative
JP2009114141A (en) * 2007-11-08 2009-05-28 Daiichi Sankyo Co Ltd Azacycloalkane carboxylic acid derivative

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3452079A (en) * 1964-06-15 1969-06-24 Merck & Co Inc Acetic acid type compounds
WO2004103306A2 (en) * 2003-05-19 2004-12-02 Irm Llc Immunosuppressant compounds and compositions
US7939519B2 (en) 2003-05-19 2011-05-10 Novartis Ag Immunosuppresant compounds and compositions
WO2005082841A1 (en) * 2004-02-24 2005-09-09 Irm Llc Immunosuppressant compounds and compositions
US20070203100A1 (en) * 2004-02-24 2007-08-30 Irm Llc Immunosuppressant Compounds and Compositions
WO2008074820A1 (en) * 2006-12-21 2008-06-26 Glaxo Group Limited Oxadiazole derivatives as s1p1 receptor agonists
US20100113528A1 (en) * 2007-04-19 2010-05-06 Glaxo Group Limited Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOHNSON J E ET AL: "SYNTHESIS AND CONFIGURATIONS OF O-SUBSTITUTED HYDROXIMOYL CHLORIDES. STEREOCHEMISTRY AND MECHANISM OF ALKOXIDE ION SUBSTITUTION AT THE CARBON-NITROGEN DOUBLE BOND", JOURNAL OF ORGANIC CHEMISTRY, ACS, US, vol. 50, no. 7, 1985, pages 993 - 997, XP002031944, ISSN: 0022-3263, DOI: 10.1021/JO00207A017 *
WUTS, PETER G. M.; GREENE, THEODORE W.: "Greene's Protective Groups in Organic Synthesis", 2006, WILEY

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
WO2019013126A1 (en) 2017-07-13 2019-01-17 東レ・ファインケミカル株式会社 Production method for cycloalkyl(trifluoromethyl)benzene
US11066422B2 (en) 2017-07-13 2021-07-20 Toray Fine Chemicals Co., Ltd. Method of producing cycloalkyl(trifluoromethyl)benzene
US11390583B2 (en) 2017-09-27 2022-07-19 Dr. Reddy's Laboratories Limited Process for preparation of Siponimod, its salts and solid state forms thereof
WO2019064184A1 (en) * 2017-09-27 2019-04-04 Dr. Reddy's Laboratories Limited Process for preparation of siponimod, its salts and solid state forms thereof
WO2019064217A1 (en) 2017-09-29 2019-04-04 Novartis Ag Dosing regimen of siponimod
WO2019064212A1 (en) 2017-09-29 2019-04-04 Novartis Ag Dosing regimen of siponimod
WO2019144094A1 (en) 2018-01-22 2019-07-25 Teva Pharmaceuticals International Gmbh Crystalline siponimod fumaric acid and polymorphs thereof
US11673860B2 (en) 2018-01-22 2023-06-13 Teva Pharmaceuticals International Gmbh Crystalline siponimod fumaric acid and polymorphs thereof
WO2020161632A1 (en) * 2019-02-07 2020-08-13 Dr. Reddy’S Laboratories Limited Crystalline solid forms of siponimod
WO2020201172A1 (en) 2019-03-29 2020-10-08 Synthon B.V. Process for making siponimod and intermediate thereof
WO2021214717A1 (en) 2020-04-23 2021-10-28 Novartis Ag Dosing regimen for the use of siponimod for the treatment of acute respiratory distress syndrome
IT202000019897A1 (en) 2020-08-10 2022-02-10 Olon Spa PROCEDURE FOR THE PREPARATION OF A KEY INTERMEDIATE OF THE SIPONIMOD

Also Published As

Publication number Publication date
US20170166517A1 (en) 2017-06-15
CA2862375A1 (en) 2013-08-08
CN104105687B (en) 2018-01-02
IL249227A0 (en) 2017-01-31
KR20140121469A (en) 2014-10-15
JP2015509109A (en) 2015-03-26
CN104105687A (en) 2014-10-15
US9604914B2 (en) 2017-03-28
IL233791A0 (en) 2014-09-30
BR112014018756A8 (en) 2017-07-11
AU2013214103A1 (en) 2014-08-21
RU2014135795A (en) 2016-03-27
AU2016200557A1 (en) 2016-02-18
AU2013214103B2 (en) 2015-12-17
MX350211B (en) 2017-08-30
MX2014009352A (en) 2014-09-08
EP2809645A1 (en) 2014-12-10
US20150018577A1 (en) 2015-01-15
BR112014018756A2 (en) 2017-06-20
JP2018021040A (en) 2018-02-08
JP6209541B2 (en) 2017-10-04

Similar Documents

Publication Publication Date Title
AU2013214103B2 (en) Process for preparing N-(4-cyclohexyl-3-trifluoromethyl-benzyloxy)-acetimidic acid ethyl ester
KR101019455B1 (en) Processes for the synthesis of o-desmethylvenlafaxine
JP5850857B2 (en) Novel method for producing benzophenone derivatives
US5202447A (en) Process of producing 5,6,7-trinor-4,8-inter-m-phenylene pgi2 derivatives
TWI441812B (en) Process for the preparation of pyrazole carboxylic acid amides
JP7019500B2 (en) (9E, 11Z) -9,11-Hexadecadienyl = acetate manufacturing method
JP4094654B1 (en) Azodicarboxylic acid bis (2-alkoxyethyl) ester compound, production intermediate thereof
JP4489532B2 (en) 3-Formyl-5-trifluoromethylbenzonitrile derivative and process for producing the same
CN107021883B (en) Synthetic method and application of polysubstituted biphenyl halide liquid crystal intermediate
CN112745244B (en) Intermediate of simotimod and synthesis method thereof
US4921980A (en) Process for the preparation of N-Alkylanilines
WO2005021465A1 (en) Method for producing aromatic unsaturated compound
JP4258658B2 (en) Method for producing acetylene compound
JP2586950B2 (en) Process for producing p- or m-tert-butoxybenzaldehyde
JP2007001978A (en) Method for producing ether
CN107602337B (en) Preparation method of 1,4-dicyano-2-butene
JP4243397B2 (en) Novel unsaturated secondary alcohol and process for producing the same
JP3855686B2 (en) 3,3-dialkoxy-2-hydroxyimino derivative and process for producing the same
JP4188060B2 (en) Method for producing 1-substituted phenyl-ω-bromoalkane
CN112745244A (en) Intermediate of siponimod and synthesis method thereof
JP2003528846A (en) Process for preparing N-butyryl-4-amino-3-methyl-benzoic acid methyl ester and novel compound N- (4-bromo-2-methylphenyl) -butanamide
WO2024019180A1 (en) Production method for tafamidis or salt thereof
JP4332777B2 (en) Process for producing trifluoromethoxycyclohexanes
JPWO2004033411A1 (en) Production method of enone ester
JP2002069038A (en) Trifluoromethyl group-bearing benzoylformic alkyls, method of producing the same and method of trifluoromethyl group-bearing phenylacetic acid

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13702472

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2862375

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 233791

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2014555236

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 14376143

Country of ref document: US

Ref document number: MX/A/2014/009352

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2013702472

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2013214103

Country of ref document: AU

Date of ref document: 20130201

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20147024290

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2014135795

Country of ref document: RU

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014018756

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 249227

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 112014018756

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140730